To the best of the knowledge of our Directors, the following persons will, immediately after the completion of the Conversion and the [**REDACTED**] (without taking into account any Shares which may be issued upon the exercise of the [**REDACTED**], the exercise or vesting of any awards under the Pre-[**REDACTED**] Equity Incentive Plan or the conversion of loans under the Convertible Loan Agreements), have an interest or short position in our Shares or underlying Shares which are required to be disclosed to our Company and the Stock Exchange pursuant to the provisions of Divisions 2 and 3 of Part XV of the SFO, or will be, directly or indirectly, interested in 10% or more of the nominal value of any class of share capital carrying the rights to vote in all circumstances at the general meetings of our Company:

		As of the Latest Practicable Date		Immediately after the Conversion and the [REDACTED][(1)]	
Shareholder	**Capacity/ Nature of interest**	**Number of Shares**	**Approximate percentage of shareholding in our Company**	**Number of Shares**	**Approximate percentage of shareholding in our Company**
Dr. Wu	Interest in controlled corporation[(3)]	101,566,880	31.16%	[REDACTED]	[REDACTED]%
	Beneficial owner[(4)]	[35,519,125]	[10.90]%	[REDACTED]	[REDACTED]%
Landes Therapeutics	Beneficial owner	101,566,880	31.16%	[REDACTED]	[REDACTED]%
LDS Holdings Limited	Beneficial owner	35,905,878[(2)]	11.02%	[REDACTED]	[REDACTED]%
LC Healthcare Fund II, L.P.	Beneficial owner	31,501,749[(2)]	9.67%	[REDACTED]	[REDACTED]%
Legend Holdings Corporation	Interest in controlled corporation[(5)]	31,451,883[(2)]	9.65%	[REDACTED]	[REDACTED]%
Black Elk Peak	Beneficial owner	28,780,668[(2)]	8.83%	[REDACTED]	[REDACTED]%
NVMB III Holdings Limited	Beneficial owner	27,897,897[(2)]	8.56%	[REDACTED]	[REDACTED]%
Kaitai Capital	Interest in controlled corporation[(6)]	23,594,141[(2)]	7.24%	[REDACTED]	[REDACTED]%
Hangzhou Kaitai	Beneficial owner	20,197,057[(2)]	6.20%	[REDACTED]	[REDACTED]%

Notes:

(1) Assuming the [**REDACTED**] is not exercised and without taking into account any Shares which may be issued upon the exercise or vesting of any awards granted under the Pre-[**REDACTED**] Equity Incentive Plan or conversion of any loans under the Convertible Loan Agreements.

(2) Assuming that the relevant Preferred Shares having been converted into Shares on a one-to-one basis.

(3) Landes Therapeutics Ltd is owned as to 54.87% by Dr. Wu. Dr. Wu is therefore deemed to be interested in the 101,566,880 Shares beneficially owned by Landes Therapeutics, and is therefore interested in the Shares under the SFO.

(4) Represents the [35,519,125] Share Options granted to Dr. Wu pursuant to the Pre-[**REDACTED**] Equity Incentive Plan.

(5) Each of Legendstar I, Legendstar II and ROSY SHINE is controlled by Legend Holdings Corporation. Accordingly, Legend Holdings Corporation is deemed to be interested in the 7,854,411 Shares, 7,854,411 Shares, and 15,743,061 Shares beneficially owned by Legendstar I, Legendstar II and ROSY SHINE, respectively, under the SFO.

(6) Each of Hangzhou Kaitai Houde, Nanjing Chuangyi Kaitai and Xiamen Jingyuan Kaitai is controlled by Kaitai Capital. Accordingly, Kaitai Capital is deemed to be interested in the 20,197,057 Shares, 2,732,928 Shares and 664,156 Shares beneficially owned by Hangzhou Kaitai Houde, Nanjing Chuangyi Kaitai and Xiamen Jingyuan Kaitai, respectively, under the SFO.

Save as disclosed above, our Directors are not aware of any person who will, immediately following the Conversion and the [**REDACTED**] (without taking into account any Shares which may be issued upon the exercise of the [**REDACTED**], the exercise or vesting of any awards under the Pre-[**REDACTED**] Equity Incentive Plan, or the conversion of loans under the Convertible Loan Agreements), have an interest or short position in our Shares or underlying Shares which would be required to be disclosed to our Company and the Stock Exchange under the provisions of Divisions 2 and 3 of Part XV of the SFO, or, directly or indirectly, be interested in 10% or more of the nominal value of any class of share capital carrying rights to vote in all circumstances at general meetings of our Company.